Last news
Bombardier Ramps Up Second Test Phase of EcoJet Research Project, Sees 18-Foot-Wide Prototype Flying

Bombardier Ramps Up Second Test Phase of EcoJet Research Project, Sees 18-Foot-Wide Prototype Flying

...

Fortinet Expands Its Global SASE Points-of-Presence with Google Cloud

Fortinet Expands Its Global SASE Points-of-Presence with Google Cloud

...

Crurated Announces Exclusive Availability of Vintage Collection Wines from Domaine Robert Groffier for Both Private Buyers and Restaurants Globally

Crurated Announces Exclusive Availability of Vintage Collection Wines from Domaine Robert Groffier for Both Private Buyers and Restaurants Globally

...

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

...

Copenhagen Infrastructure Partners reaches final close of EUR ~2 billion for two new funds

Copenhagen Infrastructure Partners reaches final close of EUR ~2 billion for two new funds

...

Atos Cloud Computing, the first authorized foreign-funded company to operate data centre and cloud computing services nationwide in China, renews its Value-Added Telecommunication Services licenses

Atos Cloud Computing, the first authorized foreign-funded company to operate data centre and cloud computing services nationwide in China, renews its Value-Added Telecommunication Services licenses

...

Smart City Expo to hold in 2023 its biggest edition ever

Smart City Expo to hold in 2023 its biggest edition ever

...

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

...

1 ... 331 332 333 334 335 336 337 338 339 ... 771
menu
menu